Exploiting the defensive sugars of HIV-1 for drug and vaccine design.
The sustained effort towards developing an antibody vaccine against HIV/AIDS has provided much of our understanding of viral immunology. It is generally accepted that one of the main barriers to antibody neutralization of HIV is the array of protective structural carbohydrates that covers the antigens on the virus's surface. Intriguingly, however, recent findings suggest that these carbohydrates, which have evolved to protect HIV and promote its transmission, are also attractive therapeutic targets.
Scanlan
Christopher N
CN
Glycobiology Institute, Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK.
Offer
John
J
Zitzmann
Nicole
N
Dwek
Raymond A
RA
D016915:AIDS Vaccines / Q000737:chemistry* / Q000276:immunology*; D000818:Animals; D019380:Anti-HIV Agents / Q000494:pharmacology; D002241:Carbohydrates / Q000096:biosynthesis / Q000737:chemistry / Q000276:immunology*; D015195:Drug Design; D015488:HIV Antigens / Q000737:chemistry / Q000276:immunology; D015497:HIV-1 / Q000737:chemistry* / Q000187:drug effects / Q000276:immunology* / Q000502:physiology; D006801:Humans
D016915:AIDS Vaccines; D019380:Anti-HIV Agents; D002241:Carbohydrates; D015488:HIV Antigens